News

What Investors Need to Know About Workday's Upcoming Results

What Investors Need to Know About Workday's Upcoming Results

Insights into Workday's Quarterly Earnings Release

Workday (NASDAQ: WDAY) is preparing to share its quarterly earnings, prompting keen interest among investors. Understanding what to expect from this report can help investors make informed decisions.

Analysts predict that Workday is on track to deliver an earnings per share (EPS) of $1.72. As the date approaches, the market is abuzz with anticipation about whether Workday will exceed these expectations and provide optimistic guidance for the next quarter.

For newcomers in the investment world, it's vital to recognize that a company's guidance can have a significant impact on its stock price after earnings are announced. Therefore, staying informed about these developments is crucial.

Review of Earnings Performance History

In the previous quarter, Workday surprised analysts by reporting an EPS that was $0.10 higher than expectations, which sparked a 12.49% rise in the company's share price the next day. Such historical performance can offer valuable context as we approach the upcoming announcement.

Let's take a look at Workday's recent earnings performance:

Quarterly EPS Review:

  • Q2 2025: EPS Estimate: 1.65, Actual: 1.75 (12.0% increase)
  • Q1 2025: EPS Estimate: 1.58, Actual: 1.74 (-15.0% decrease)
  • Q4 2024: EPS Estimate: 1.47, Actual: 1.57 (-4.0% decrease)
  • Q3 2024: EPS Estimate: 1.41, Actual: 1.53 (11.0% increase)

Current Stock Performance Overview

As of the latest report on November 22, Workday's shares were trading at $267.75. During the past year, the stock has appreciated by 14.59%. These encouraging returns may bode well for long-term shareholders as we look forward to the quarterly earnings announcement.

Market Analysts' Perspectives

Market sentiment plays a pivotal role in shaping investor strategies. Currently, the consensus rating for Workday is designated as a Buy, based on feedback from 10 analysts. The average one-year price target is set at $298.5, suggesting a potential upside of approximately 11.48% from the current price.

Workday's Peers and Comparative Analysis

When evaluating Workday’s positioning in the market, it’s beneficial to compare it with other prominent players in the industry, such as Autodesk, Atlassian, and Roper Technologies. Here’s how they stack up:

  • Autodesk: Analysts anticipate an Outperform rating with a price target of $316.65, indicating a potential upside of 18.26%.
  • Atlassian: The consensus remains an Outperform, although the average price target of $242.58 signals a potential downside of 9.4%.
  • Roper Technologies: Rated as a Buy, with an impressive price target of $641.6, suggesting a substantial upside of 139.63%.

Summary of Peer Analysis Metrics

When examining key performance indicators for Workday, it ranks first among its peers for revenue growth but falls short in gross profit and return on equity metrics:

  • Workday: Revenue Growth: 16.68%, Gross Profit: $1.57B, Return on Equity: 1.60%
  • Autodesk: Revenue Growth: 11.90%, Gross Profit: $1.36B, Return on Equity: 12.17%
  • Atlassian: Revenue Growth: 21.48%, Gross Profit: $970.16M, Return on Equity: -12.01%
  • Roper Technologies: Revenue Growth: 12.87%, Gross Profit: $1.22B, Return on Equity: 2.01%

Getting to Know Workday

Workday has established itself as a leader in the software industry, providing solutions for human capital management, financial management, and business planning. As a purely cloud-based software entity, the company is headquartered in Pleasanton, California, and has grown significantly since its inception in 2005, now employing over 18,000 individuals.

Financial Performance Analysis of Workday

Market Capitalization: Workday's market capitalization remains below the industry average; this could be a result of its perceived growth potential or scale.

Revenue Growth Assessment: Workday's reported revenue growth rate of 16.68% signifies a healthy upward trend in earnings. This growth outpaces many of its peers in the Information Technology sector, highlighting its robust performance.

Net Margin Metrics: The company's net margin stands at 6.33%, indicating sound profitability and competent cost efficiency compared to industry standards.

Return on Equity (ROE) Insights: With an ROE of 1.60%, Workday might face challenges in delivering optimal returns for shareholders, necessitating strategic adjustments to enhance returns on equity.

Return on Assets (ROA) Overview: Workday also experiences a lower ROA of 0.82%, suggesting a need for improved asset utilization to optimize returns.

Debt Management Practices: The company maintains a prudent approach to debt with a favorable debt-to-equity ratio of 0.4, indicating a balanced financial strategy.

Frequently Asked Questions

What is the expected EPS for Workday's upcoming earnings report?

Analysts are forecasting an EPS of $1.72 for the upcoming quarterly earnings release.

How has Workday performed in the past quarters?

In the last quarter, Workday beat EPS estimates, leading to a notable increase in share price the following day.

What is Workday's current share price trend?

As of late November, Workday shares are up by 14.59% over the past year.

What is the general sentiment among analysts regarding Workday?

The consensus rating for Workday is a Buy, with a favorable outlook from multiple analysts.

How does Workday compare to its industry peers?

Workday shows strong revenue growth compared to its peers, although it lags in terms of gross profit and ROE.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading